| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 103 | 2026 | 1723 | 11.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 36 | 2025 | 760 | 9.320 |
Why?
|
| Diet | 56 | 2025 | 826 | 8.350 |
Why?
|
| Mammography | 56 | 2024 | 212 | 7.180 |
Why?
|
| Breast | 32 | 2019 | 139 | 6.330 |
Why?
|
| Soy Foods | 22 | 2016 | 60 | 5.710 |
Why?
|
| Premenopause | 39 | 2021 | 110 | 5.700 |
Why?
|
| Adiposity | 18 | 2025 | 157 | 4.800 |
Why?
|
| Cohort Studies | 69 | 2026 | 1759 | 4.560 |
Why?
|
| Isoflavones | 27 | 2021 | 132 | 4.490 |
Why?
|
| Body Mass Index | 54 | 2026 | 925 | 4.440 |
Why?
|
| Obesity | 28 | 2026 | 1151 | 4.430 |
Why?
|
| Risk Factors | 104 | 2026 | 3994 | 4.220 |
Why?
|
| Middle Aged | 164 | 2026 | 12222 | 3.900 |
Why?
|
| Aged | 124 | 2026 | 8214 | 3.880 |
Why?
|
| Female | 224 | 2026 | 24698 | 3.770 |
Why?
|
| Intra-Abdominal Fat | 10 | 2025 | 46 | 3.700 |
Why?
|
| Hawaii | 78 | 2026 | 2011 | 3.320 |
Why?
|
| Humans | 238 | 2026 | 43102 | 3.070 |
Why?
|
| Mammary Glands, Human | 10 | 2024 | 40 | 3.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 11 | 2023 | 40 | 2.940 |
Why?
|
| Incidence | 37 | 2026 | 1078 | 2.840 |
Why?
|
| Estrogens | 11 | 2016 | 203 | 2.820 |
Why?
|
| Feeding Behavior | 15 | 2018 | 469 | 2.260 |
Why?
|
| Life Style | 9 | 2025 | 334 | 2.140 |
Why?
|
| Adult | 106 | 2026 | 13872 | 2.130 |
Why?
|
| Proportional Hazards Models | 31 | 2025 | 518 | 2.100 |
Why?
|
| Overweight | 8 | 2023 | 249 | 2.080 |
Why?
|
| Prospective Studies | 36 | 2025 | 1600 | 2.060 |
Why?
|
| Absorptiometry, Photon | 14 | 2026 | 76 | 2.040 |
Why?
|
| Colorectal Neoplasms | 9 | 2024 | 512 | 1.970 |
Why?
|
| Subcutaneous Fat | 3 | 2025 | 19 | 1.950 |
Why?
|
| Case-Control Studies | 37 | 2024 | 1285 | 1.900 |
Why?
|
| Male | 93 | 2026 | 23409 | 1.850 |
Why?
|
| Nipple Aspirate Fluid | 5 | 2013 | 14 | 1.840 |
Why?
|
| Diet, Mediterranean | 5 | 2020 | 37 | 1.540 |
Why?
|
| Postmenopause | 18 | 2020 | 141 | 1.480 |
Why?
|
| Inflammation | 8 | 2022 | 758 | 1.400 |
Why?
|
| Japan | 21 | 2019 | 348 | 1.360 |
Why?
|
| Cross-Sectional Studies | 35 | 2025 | 3156 | 1.350 |
Why?
|
| California | 16 | 2024 | 548 | 1.310 |
Why?
|
| C-Reactive Protein | 10 | 2022 | 167 | 1.200 |
Why?
|
| Health Behavior | 7 | 2015 | 575 | 1.200 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2025 | 587 | 1.190 |
Why?
|
| Follow-Up Studies | 20 | 2025 | 1067 | 1.170 |
Why?
|
| Leptin | 9 | 2018 | 118 | 1.150 |
Why?
|
| Insulin-Like Growth Factor I | 7 | 2016 | 81 | 1.150 |
Why?
|
| Soybean Proteins | 5 | 2014 | 38 | 1.100 |
Why?
|
| Body Composition | 7 | 2026 | 159 | 1.040 |
Why?
|
| Meat | 6 | 2024 | 46 | 1.030 |
Why?
|
| Sleep | 2 | 2019 | 185 | 0.990 |
Why?
|
| Adiponectin | 6 | 2017 | 59 | 0.950 |
Why?
|
| Nutrition Assessment | 5 | 2018 | 80 | 0.920 |
Why?
|
| Body Fat Distribution | 3 | 2021 | 26 | 0.910 |
Why?
|
| Smoking | 14 | 2025 | 1024 | 0.900 |
Why?
|
| Parity | 5 | 2024 | 59 | 0.890 |
Why?
|
| Cross-Over Studies | 11 | 2021 | 115 | 0.890 |
Why?
|
| Gonadal Steroid Hormones | 4 | 2024 | 55 | 0.880 |
Why?
|
| Cacao | 2 | 2018 | 10 | 0.860 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 6 | 2010 | 27 | 0.850 |
Why?
|
| Survivors | 4 | 2015 | 152 | 0.830 |
Why?
|
| Muscles | 1 | 2023 | 82 | 0.820 |
Why?
|
| Alcohol Drinking | 6 | 2025 | 609 | 0.810 |
Why?
|
| Body Weight | 5 | 2015 | 429 | 0.790 |
Why?
|
| Micronutrients | 3 | 2019 | 45 | 0.780 |
Why?
|
| Prostatic Neoplasms | 4 | 2024 | 1092 | 0.780 |
Why?
|
| Feces | 3 | 2021 | 132 | 0.770 |
Why?
|
| Adolescent | 26 | 2026 | 6081 | 0.720 |
Why?
|
| Tocopherols | 3 | 2021 | 65 | 0.720 |
Why?
|
| Nipples | 3 | 2013 | 20 | 0.710 |
Why?
|
| Dietary Fiber | 3 | 2020 | 51 | 0.710 |
Why?
|
| Neoplasms | 11 | 2024 | 1377 | 0.710 |
Why?
|
| Aged, 80 and over | 18 | 2024 | 2853 | 0.700 |
Why?
|
| Diabetes Mellitus | 7 | 2019 | 539 | 0.690 |
Why?
|
| United States | 16 | 2023 | 5205 | 0.690 |
Why?
|
| Chronic Disease | 2 | 2019 | 549 | 0.680 |
Why?
|
| Logistic Models | 12 | 2017 | 1009 | 0.670 |
Why?
|
| Mortality | 2 | 2016 | 175 | 0.640 |
Why?
|
| Phytoestrogens | 4 | 2013 | 39 | 0.620 |
Why?
|
| Flavonoids | 2 | 2018 | 100 | 0.610 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2011 | 36 | 0.600 |
Why?
|
| Lipids | 3 | 2018 | 256 | 0.600 |
Why?
|
| Hydroxyestrones | 4 | 2017 | 8 | 0.590 |
Why?
|
| Thinness | 1 | 2019 | 32 | 0.590 |
Why?
|
| Estradiol | 6 | 2024 | 268 | 0.590 |
Why?
|
| Coffee | 2 | 2023 | 20 | 0.590 |
Why?
|
| Reproductive History | 2 | 2024 | 27 | 0.580 |
Why?
|
| Risk Assessment | 11 | 2020 | 863 | 0.570 |
Why?
|
| Vimentin | 1 | 2018 | 44 | 0.570 |
Why?
|
| Estrone | 4 | 2013 | 21 | 0.570 |
Why?
|
| Anticarcinogenic Agents | 2 | 2009 | 77 | 0.560 |
Why?
|
| Receptors, Progesterone | 4 | 2019 | 92 | 0.560 |
Why?
|
| Puberty | 2 | 2011 | 31 | 0.560 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 100 | 0.550 |
Why?
|
| Patient Compliance | 6 | 2012 | 233 | 0.550 |
Why?
|
| Los Angeles | 13 | 2021 | 394 | 0.550 |
Why?
|
| Medicare | 5 | 2023 | 332 | 0.550 |
Why?
|
| Oxidative Stress | 2 | 2015 | 1003 | 0.530 |
Why?
|
| Pilot Projects | 11 | 2026 | 760 | 0.530 |
Why?
|
| Meat Products | 1 | 2017 | 5 | 0.530 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 140 | 0.530 |
Why?
|
| Anthropometry | 5 | 2023 | 97 | 0.520 |
Why?
|
| Exercise | 5 | 2025 | 692 | 0.520 |
Why?
|
| Time Factors | 9 | 2019 | 1857 | 0.520 |
Why?
|
| Age Factors | 12 | 2015 | 1154 | 0.510 |
Why?
|
| Receptors, Estrogen | 3 | 2019 | 183 | 0.510 |
Why?
|
| Carotenoids | 5 | 2021 | 74 | 0.500 |
Why?
|
| Weight Gain | 2 | 2023 | 139 | 0.500 |
Why?
|
| Chromatography, Liquid | 3 | 2014 | 182 | 0.500 |
Why?
|
| Sepsis | 1 | 2017 | 90 | 0.490 |
Why?
|
| Gene Expression | 2 | 2018 | 701 | 0.490 |
Why?
|
| Odds Ratio | 9 | 2019 | 587 | 0.460 |
Why?
|
| gamma-Tocopherol | 4 | 2019 | 19 | 0.460 |
Why?
|
| Antioxidants | 4 | 2015 | 443 | 0.440 |
Why?
|
| Phenotype | 8 | 2024 | 780 | 0.440 |
Why?
|
| Plant Preparations | 2 | 2013 | 24 | 0.430 |
Why?
|
| Reproducibility of Results | 8 | 2018 | 1081 | 0.430 |
Why?
|
| Prognosis | 11 | 2019 | 861 | 0.430 |
Why?
|
| Liver | 1 | 2017 | 511 | 0.420 |
Why?
|
| Adipokines | 1 | 2014 | 28 | 0.420 |
Why?
|
| Stroke | 1 | 2018 | 340 | 0.410 |
Why?
|
| Health Status Disparities | 3 | 2015 | 719 | 0.410 |
Why?
|
| Survival Rate | 7 | 2018 | 355 | 0.400 |
Why?
|
| Survival Analysis | 5 | 2020 | 368 | 0.400 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2011 | 13 | 0.400 |
Why?
|
| Mass Spectrometry | 2 | 2012 | 280 | 0.400 |
Why?
|
| Epithelial Cells | 2 | 2013 | 434 | 0.400 |
Why?
|
| Menstrual Cycle | 2 | 2004 | 36 | 0.400 |
Why?
|
| Coffea | 1 | 2013 | 2 | 0.400 |
Why?
|
| Attitude to Health | 3 | 2005 | 338 | 0.390 |
Why?
|
| Tissue Array Analysis | 2 | 2013 | 80 | 0.390 |
Why?
|
| Child | 13 | 2026 | 3443 | 0.390 |
Why?
|
| Population Groups | 2 | 2022 | 59 | 0.390 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2024 | 863 | 0.380 |
Why?
|
| Erythrocyte Membrane | 1 | 2012 | 20 | 0.380 |
Why?
|
| Vitamin D | 6 | 2023 | 196 | 0.380 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2009 | 146 | 0.380 |
Why?
|
| Multifactorial Inheritance | 2 | 2025 | 34 | 0.380 |
Why?
|
| Phytotherapy | 1 | 2012 | 75 | 0.370 |
Why?
|
| Isoprostanes | 1 | 2012 | 13 | 0.370 |
Why?
|
| Oncology Service, Hospital | 1 | 2012 | 3 | 0.370 |
Why?
|
| Women's Health | 2 | 2011 | 160 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2025 | 734 | 0.360 |
Why?
|
| Fatty Acids | 1 | 2012 | 134 | 0.350 |
Why?
|
| RNA, Ribosomal, 16S | 4 | 2022 | 203 | 0.350 |
Why?
|
| Eating | 4 | 2022 | 167 | 0.350 |
Why?
|
| Steroids | 1 | 2011 | 45 | 0.340 |
Why?
|
| Cytochrome P-450 CYP1A2 | 3 | 2007 | 28 | 0.340 |
Why?
|
| Young Adult | 10 | 2025 | 5080 | 0.340 |
Why?
|
| Vitamin D Deficiency | 4 | 2023 | 107 | 0.330 |
Why?
|
| Blood Glucose | 2 | 2010 | 389 | 0.330 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2012 | 458 | 0.330 |
Why?
|
| Complementary Therapies | 6 | 2012 | 51 | 0.330 |
Why?
|
| Motor Activity | 3 | 2015 | 437 | 0.330 |
Why?
|
| Prevalence | 8 | 2012 | 1612 | 0.320 |
Why?
|
| Genome-Wide Association Study | 6 | 2024 | 423 | 0.320 |
Why?
|
| Internship and Residency | 1 | 2012 | 146 | 0.320 |
Why?
|
| Confidence Intervals | 5 | 2013 | 162 | 0.320 |
Why?
|
| SEER Program | 6 | 2019 | 164 | 0.320 |
Why?
|
| Linear Models | 6 | 2021 | 317 | 0.320 |
Why?
|
| Neoplasm Staging | 7 | 2011 | 374 | 0.320 |
Why?
|
| Longitudinal Studies | 6 | 2019 | 1063 | 0.310 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 934 | 0.310 |
Why?
|
| Menopause | 3 | 2007 | 64 | 0.310 |
Why?
|
| Philippines | 2 | 2024 | 81 | 0.310 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 440 | 0.300 |
Why?
|
| Plant Extracts | 1 | 2012 | 302 | 0.300 |
Why?
|
| Magnesium | 1 | 2009 | 94 | 0.300 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2009 | 6 | 0.300 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 18 | 0.300 |
Why?
|
| Waist Circumference | 2 | 2023 | 90 | 0.290 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2007 | 18 | 0.280 |
Why?
|
| Regression Analysis | 7 | 2015 | 490 | 0.280 |
Why?
|
| Risk | 5 | 2014 | 287 | 0.280 |
Why?
|
| Lymphoma, Follicular | 1 | 2008 | 3 | 0.280 |
Why?
|
| Hormones | 2 | 2013 | 55 | 0.280 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 11 | 0.280 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 21 | 0.270 |
Why?
|
| Lymphoma, T-Cell | 1 | 2008 | 29 | 0.270 |
Why?
|
| Lymphoma, B-Cell | 1 | 2008 | 28 | 0.270 |
Why?
|
| Prolactin | 1 | 2007 | 65 | 0.270 |
Why?
|
| Comorbidity | 4 | 2018 | 737 | 0.270 |
Why?
|
| Adipose Tissue | 5 | 2021 | 182 | 0.260 |
Why?
|
| Sex Factors | 8 | 2013 | 1028 | 0.260 |
Why?
|
| Fruit | 5 | 2021 | 178 | 0.260 |
Why?
|
| Norway | 7 | 2016 | 10 | 0.260 |
Why?
|
| Diet Surveys | 6 | 2009 | 99 | 0.250 |
Why?
|
| Vegetables | 4 | 2021 | 147 | 0.250 |
Why?
|
| Progesterone | 4 | 2012 | 121 | 0.250 |
Why?
|
| Health Status Indicators | 1 | 2007 | 90 | 0.250 |
Why?
|
| Interleukin-6 | 3 | 2014 | 165 | 0.250 |
Why?
|
| Radiographic Image Enhancement | 1 | 2006 | 7 | 0.240 |
Why?
|
| Population Surveillance | 5 | 2012 | 246 | 0.240 |
Why?
|
| Obesity, Abdominal | 2 | 2019 | 29 | 0.240 |
Why?
|
| China | 4 | 2012 | 229 | 0.240 |
Why?
|
| Germany | 1 | 2025 | 26 | 0.240 |
Why?
|
| Heptachlor | 1 | 2005 | 2 | 0.230 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2026 | 94 | 0.230 |
Why?
|
| Cause of Death | 2 | 2018 | 186 | 0.220 |
Why?
|
| Cholesterol, HDL | 2 | 2017 | 99 | 0.220 |
Why?
|
| Areca | 1 | 2025 | 33 | 0.220 |
Why?
|
| Triglycerides | 2 | 2017 | 147 | 0.220 |
Why?
|
| Models, Genetic | 1 | 2025 | 183 | 0.220 |
Why?
|
| Food Contamination | 1 | 2005 | 57 | 0.220 |
Why?
|
| Family Health | 2 | 2017 | 55 | 0.220 |
Why?
|
| Insecticides | 1 | 2005 | 54 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2010 | 375 | 0.210 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2024 | 12 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2018 | 384 | 0.210 |
Why?
|
| Iceland | 2 | 2022 | 5 | 0.200 |
Why?
|
| Sarcopenia | 1 | 2023 | 15 | 0.200 |
Why?
|
| Emigration and Immigration | 1 | 2004 | 85 | 0.200 |
Why?
|
| Sex Hormone-Binding Globulin | 4 | 2024 | 25 | 0.200 |
Why?
|
| Pregnancy | 4 | 2024 | 1772 | 0.200 |
Why?
|
| Malnutrition | 1 | 2023 | 44 | 0.200 |
Why?
|
| Registries | 6 | 2019 | 437 | 0.190 |
Why?
|
| Sex Distribution | 3 | 2011 | 224 | 0.190 |
Why?
|
| Testosterone | 3 | 2024 | 211 | 0.180 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 89 | 0.180 |
Why?
|
| Mastectomy, Segmental | 1 | 2002 | 25 | 0.180 |
Why?
|
| Cell Count | 2 | 2012 | 145 | 0.180 |
Why?
|
| Insurance Claim Review | 1 | 2002 | 37 | 0.180 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2013 | 465 | 0.180 |
Why?
|
| Whole Body Imaging | 1 | 2021 | 25 | 0.180 |
Why?
|
| Body Height | 1 | 2022 | 53 | 0.180 |
Why?
|
| Health Surveys | 4 | 2012 | 405 | 0.170 |
Why?
|
| Vitamin A | 1 | 2021 | 86 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2018 | 174 | 0.170 |
Why?
|
| Genistein | 2 | 2013 | 45 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2002 | 341 | 0.160 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 561 | 0.160 |
Why?
|
| Metformin | 1 | 2021 | 75 | 0.160 |
Why?
|
| Tamoxifen | 2 | 2018 | 69 | 0.160 |
Why?
|
| Prediabetic State | 1 | 2021 | 69 | 0.160 |
Why?
|
| Nutrition Surveys | 2 | 2014 | 263 | 0.160 |
Why?
|
| Retrospective Studies | 5 | 2023 | 2544 | 0.160 |
Why?
|
| Glucose | 1 | 2021 | 244 | 0.150 |
Why?
|
| Calcifediol | 2 | 2023 | 17 | 0.150 |
Why?
|
| Diet, Reducing | 1 | 2019 | 23 | 0.150 |
Why?
|
| Caloric Restriction | 1 | 2019 | 34 | 0.150 |
Why?
|
| Double-Blind Method | 3 | 2017 | 317 | 0.140 |
Why?
|
| Radiation, Ionizing | 1 | 2018 | 13 | 0.140 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 611 | 0.140 |
Why?
|
| Arizona | 3 | 2007 | 139 | 0.140 |
Why?
|
| Flavanones | 1 | 2018 | 15 | 0.140 |
Why?
|
| Aging | 2 | 2017 | 783 | 0.140 |
Why?
|
| Bacteria | 1 | 2021 | 293 | 0.140 |
Why?
|
| France | 1 | 2017 | 23 | 0.130 |
Why?
|
| Perimenopause | 1 | 2017 | 7 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 2 | 2016 | 121 | 0.130 |
Why?
|
| Singapore | 2 | 2010 | 33 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2008 | 259 | 0.130 |
Why?
|
| Energy Intake | 2 | 2015 | 164 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2017 | 48 | 0.130 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 236 | 0.130 |
Why?
|
| Soy Milk | 2 | 2008 | 6 | 0.120 |
Why?
|
| Body Image | 1 | 2017 | 89 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 20 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 218 | 0.120 |
Why?
|
| Diet Records | 2 | 2014 | 58 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2015 | 7 | 0.120 |
Why?
|
| Indoles | 1 | 2017 | 187 | 0.120 |
Why?
|
| Creatinine | 2 | 2014 | 102 | 0.120 |
Why?
|
| F2-Isoprostanes | 1 | 2015 | 18 | 0.120 |
Why?
|
| Canada | 1 | 2016 | 163 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2017 | 201 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2015 | 64 | 0.110 |
Why?
|
| Animals | 4 | 2024 | 16992 | 0.110 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 201 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 220 | 0.110 |
Why?
|
| Food | 1 | 2015 | 103 | 0.110 |
Why?
|
| Kallikreins | 1 | 2014 | 11 | 0.110 |
Why?
|
| alpha-Tocopherol | 1 | 2014 | 27 | 0.110 |
Why?
|
| Ubiquinone | 1 | 2014 | 23 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2015 | 192 | 0.100 |
Why?
|
| Luteal Phase | 1 | 2013 | 6 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2016 | 321 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2014 | 95 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 241 | 0.100 |
Why?
|
| Cross-Cultural Comparison | 2 | 2004 | 111 | 0.100 |
Why?
|
| Educational Status | 3 | 2015 | 339 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 3 | 2015 | 49 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 290 | 0.100 |
Why?
|
| Colonoscopy | 1 | 2014 | 122 | 0.100 |
Why?
|
| Parturition | 1 | 2013 | 22 | 0.100 |
Why?
|
| Adolescent Behavior | 2 | 2007 | 281 | 0.100 |
Why?
|
| Caffeine | 1 | 2013 | 28 | 0.100 |
Why?
|
| Infant | 2 | 2008 | 1175 | 0.100 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 147 | 0.100 |
Why?
|
| Matrix Metalloproteinases | 1 | 2012 | 49 | 0.090 |
Why?
|
| Minnesota | 1 | 2012 | 41 | 0.090 |
Why?
|
| Causality | 1 | 2012 | 45 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 415 | 0.090 |
Why?
|
| Waist-Hip Ratio | 1 | 2012 | 34 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 749 | 0.090 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2009 | 47 | 0.090 |
Why?
|
| Korea | 1 | 2012 | 37 | 0.090 |
Why?
|
| Dietary Supplements | 2 | 2005 | 213 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2008 | 1546 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 72 | 0.090 |
Why?
|
| Food Analysis | 1 | 2011 | 34 | 0.090 |
Why?
|
| Mexican Americans | 1 | 2014 | 226 | 0.090 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 70 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2013 | 346 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2011 | 4 | 0.090 |
Why?
|
| Mass Screening | 2 | 2014 | 541 | 0.090 |
Why?
|
| Physician-Patient Relations | 2 | 2003 | 148 | 0.090 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2011 | 24 | 0.090 |
Why?
|
| Limit of Detection | 1 | 2011 | 94 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 31 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2022 | 1604 | 0.080 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 1234 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2010 | 4 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 5 | 0.080 |
Why?
|
| Cholesterol | 1 | 2012 | 232 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 116 | 0.080 |
Why?
|
| Hypertension | 1 | 2017 | 835 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2015 | 735 | 0.080 |
Why?
|
| Epidemiologic Studies | 1 | 2010 | 33 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1070 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 638 | 0.080 |
Why?
|
| Ethanol | 1 | 2012 | 224 | 0.080 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 457 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 236 | 0.080 |
Why?
|
| Immune System Diseases | 1 | 2009 | 21 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2012 | 497 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1455 | 0.080 |
Why?
|
| Placebos | 1 | 2009 | 41 | 0.080 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2009 | 21 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1124 | 0.070 |
Why?
|
| Chemokine CCL4 | 1 | 2008 | 19 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2009 | 41 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 34 | 0.070 |
Why?
|
| Mothers | 1 | 2011 | 215 | 0.070 |
Why?
|
| Cytokines | 1 | 2013 | 678 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2008 | 38 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 241 | 0.070 |
Why?
|
| Genotype | 4 | 2015 | 800 | 0.070 |
Why?
|
| Bone Density | 1 | 2009 | 103 | 0.070 |
Why?
|
| Quality of Life | 4 | 2012 | 616 | 0.070 |
Why?
|
| Patient Satisfaction | 3 | 2005 | 165 | 0.070 |
Why?
|
| Urinalysis | 2 | 2005 | 34 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 968 | 0.070 |
Why?
|
| Fermentation | 1 | 2008 | 39 | 0.070 |
Why?
|
| Dairy Products | 2 | 2005 | 34 | 0.070 |
Why?
|
| Asia | 2 | 2006 | 98 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2008 | 95 | 0.070 |
Why?
|
| Research Design | 2 | 2007 | 385 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2010 | 430 | 0.070 |
Why?
|
| Sex Characteristics | 1 | 2009 | 258 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 27 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2008 | 63 | 0.070 |
Why?
|
| Social Class | 1 | 2009 | 291 | 0.070 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2008 | 140 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2007 | 575 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 228 | 0.060 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2006 | 26 | 0.060 |
Why?
|
| Androstenedione | 1 | 2006 | 19 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 259 | 0.060 |
Why?
|
| Social Identification | 1 | 2007 | 65 | 0.060 |
Why?
|
| Aspirin | 1 | 2007 | 89 | 0.060 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 235 | 0.060 |
Why?
|
| Mental Recall | 2 | 2003 | 84 | 0.060 |
Why?
|
| Androgens | 1 | 2006 | 106 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 113 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2005 | 223 | 0.060 |
Why?
|
| Mastication | 1 | 2025 | 24 | 0.060 |
Why?
|
| Europe | 3 | 2011 | 115 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 107 | 0.060 |
Why?
|
| ROC Curve | 1 | 2005 | 159 | 0.060 |
Why?
|
| Pregnanediol | 1 | 2005 | 4 | 0.060 |
Why?
|
| Estriol | 1 | 2005 | 9 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2005 | 44 | 0.060 |
Why?
|
| Lymphoma | 1 | 2005 | 41 | 0.050 |
Why?
|
| Gene Dosage | 1 | 2004 | 75 | 0.050 |
Why?
|
| Poultry | 1 | 2024 | 13 | 0.050 |
Why?
|
| Leukemia | 1 | 2005 | 54 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 83 | 0.050 |
Why?
|
| Research | 1 | 2006 | 181 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2005 | 82 | 0.050 |
Why?
|
| Students | 2 | 2007 | 626 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2005 | 98 | 0.050 |
Why?
|
| Self Concept | 1 | 2005 | 171 | 0.050 |
Why?
|
| Insurance Claim Reporting | 1 | 2003 | 5 | 0.050 |
Why?
|
| Communication | 2 | 2003 | 210 | 0.050 |
Why?
|
| Electric Impedance | 1 | 2023 | 28 | 0.050 |
Why?
|
| Information Services | 1 | 2003 | 13 | 0.050 |
Why?
|
| History, 17th Century | 1 | 2002 | 5 | 0.050 |
Why?
|
| Dietary Fats | 3 | 2009 | 117 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2024 | 126 | 0.050 |
Why?
|
| Spirituality | 1 | 2003 | 53 | 0.050 |
Why?
|
| Weight Loss | 1 | 2023 | 137 | 0.050 |
Why?
|
| Menarche | 1 | 2022 | 15 | 0.050 |
Why?
|
| Health Systems Plans | 1 | 2002 | 1 | 0.050 |
Why?
|
| Palpation | 1 | 2022 | 3 | 0.050 |
Why?
|
| Patients | 1 | 2002 | 16 | 0.050 |
Why?
|
| Growth | 1 | 2022 | 11 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2002 | 20 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2002 | 61 | 0.050 |
Why?
|
| Sunlight | 2 | 2014 | 48 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2002 | 43 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2015 | 101 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2022 | 35 | 0.040 |
Why?
|
| Mice | 1 | 2013 | 6644 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2005 | 972 | 0.040 |
Why?
|
| Smoking Cessation | 2 | 2007 | 590 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 95 | 0.040 |
Why?
|
| Interpersonal Relations | 1 | 2003 | 222 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 239 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2005 | 989 | 0.040 |
Why?
|
| Medicaid | 1 | 2002 | 143 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 420 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 706 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2018 | 32 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 449 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2016 | 24 | 0.030 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2016 | 20 | 0.030 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 57 | 0.030 |
Why?
|
| International Agencies | 1 | 2015 | 6 | 0.030 |
Why?
|
| Algorithms | 1 | 2019 | 509 | 0.030 |
Why?
|
| Water | 1 | 2018 | 316 | 0.030 |
Why?
|
| Models, Biological | 1 | 2019 | 712 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 118 | 0.030 |
Why?
|
| Luciferases | 1 | 2015 | 71 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 88 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 199 | 0.030 |
Why?
|
| Clostridium | 1 | 2014 | 24 | 0.030 |
Why?
|
| Schools | 2 | 2007 | 283 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 17 | 0.030 |
Why?
|
| Bacterial Typing Techniques | 1 | 2014 | 37 | 0.030 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 16 | 0.030 |
Why?
|
| Actinobacteria | 1 | 2014 | 14 | 0.030 |
Why?
|
| Uric Acid | 1 | 2014 | 29 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 983 | 0.030 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2012 | 6 | 0.020 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 51 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1082 | 0.020 |
Why?
|
| Beer | 1 | 2011 | 4 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 92 | 0.020 |
Why?
|
| Wine | 1 | 2011 | 9 | 0.020 |
Why?
|
| Carbonated Beverages | 1 | 2011 | 21 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 34 | 0.020 |
Why?
|
| Beverages | 1 | 2011 | 66 | 0.020 |
Why?
|
| Finland | 1 | 2010 | 15 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 35 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 2009 | 6 | 0.020 |
Why?
|
| Seasons | 1 | 2010 | 139 | 0.020 |
Why?
|
| Health Promotion | 2 | 2007 | 704 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2009 | 39 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 352 | 0.020 |
Why?
|
| Milk | 1 | 2009 | 56 | 0.020 |
Why?
|
| Hyperparathyroidism | 1 | 2009 | 5 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 162 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 310 | 0.020 |
Why?
|
| Nicaragua | 1 | 2006 | 8 | 0.020 |
Why?
|
| New Zealand | 1 | 2006 | 32 | 0.020 |
Why?
|
| Africa | 1 | 2006 | 82 | 0.020 |
Why?
|
| Cultural Characteristics | 1 | 2007 | 128 | 0.020 |
Why?
|
| Australia | 1 | 2006 | 103 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2007 | 126 | 0.020 |
Why?
|
| School Health Services | 1 | 2007 | 90 | 0.010 |
Why?
|
| Peer Group | 1 | 2007 | 177 | 0.010 |
Why?
|
| Menstruation | 1 | 2005 | 11 | 0.010 |
Why?
|
| Social Behavior | 1 | 2007 | 161 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2007 | 359 | 0.010 |
Why?
|
| Narration | 1 | 2005 | 37 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 211 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2005 | 21 | 0.010 |
Why?
|
| Mastectomy | 1 | 2005 | 21 | 0.010 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2004 | 18 | 0.010 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2004 | 39 | 0.010 |
Why?
|
| Self Care | 1 | 2005 | 175 | 0.010 |
Why?
|
| Faith Healing | 1 | 2003 | 4 | 0.010 |
Why?
|
| Anecdotes as Topic | 1 | 2003 | 6 | 0.010 |
Why?
|
| Pacific Islands | 1 | 2003 | 123 | 0.010 |
Why?
|
| Professional Practice | 1 | 2002 | 6 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 64 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 2002 | 63 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 2002 | 76 | 0.010 |
Why?
|
| Culture | 1 | 2003 | 172 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 452 | 0.010 |
Why?
|
| Motivation | 1 | 2004 | 513 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 231 | 0.010 |
Why?
|
| Social Support | 1 | 2003 | 445 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 1019 | 0.010 |
Why?
|